PhD position - Drug Development

"Knowledge becomes health" - we are filling this motto with life every day, developing new ideas and improv-ing old-established knowledge. The University Hospital Frankfurt has existed since 1914. Our around 8,500 employees contribute with their skills and knowledge to the 33 specialist clinics, theoretical clinical institutes, and administrative departments. The close connection of health care with research and teaching, as well as a climate of collegiality, internationality, and cross-professional cooperation characterize the university hospital. We are seeking a highly motivated PhD student to join our teams at the Oellerich lab at the Department of Medicine 2 , Universitätsmedizin Frankfurt and the Knapp lab at Goethe University , starting from the earliest possible date. The Department of Medicine 2, Hematology and Oncology at the Goethe University Hospital Frankfurt offers the entire spectrum of cancer diagnostics and therapy as well as a research program focusing on several cancer entities. The laboratory of Prof. Stefan Knapp is part of the Institute of Pharma-ceutical Chemistry of the Department of Biochemistry, Chemistry and Pharmacy of the Goethe University Frankfurt am Main as well as the site head of the Structural Genomics consortium (SGC) in Frankfurt. The group is particularly interested in understanding structural mechanisms that regulate cellular signaling and in the development and rational design of selective inhibitors, so-called chemical probes, especially in the field of epigenetics, phosphoryla-tion-dependent signaling pathways, and the development of PROTAC. The two research laboratories are part of the Frankfurt Cancer Institute ( https://fci.health ), focusing on oncogenic signaling and therapy resistance mechanisms in lymphoma and acute myeloid leukemia ( http://lymphoma-leukemia-research-frankfurt.de/ ) and development of new therapeutic ap-proaches to advance them to the development of new drugs. ( https://fci.health/en/research/research-areas/p4-drug-development/ ), respec-tively. The labs are also funded by the German Cancer Consortium (DKTK), which was founded in 2012 as one of the six German Centers of Excellence for Health Research (DZG) to promote the clinical translation of medical inno-vations. The DKTK brings together more than 20 academic research institutions and university hospitals at seven partner sites cooperate with each other and the German Cancer Research Center (DKFZ) in Heidelberg as the core center ( https://www.dkfz.de/de/dktk/ ). Translational projects are part of the German Cancer Aid (Krebshilfe) Network TACTIC that is coordinated by the Knapp Group allowing access to assay platforms for the development of pre-clinical small molecules.